Prevention of Human Papillomavirus (HPV) Infection in Paediatric Kidney and Liver Transplant Recipients and in Paediatric Patients With Advanced Chronic Kidney Disease
- Conditions
- Chronic Kidney DiseasePaediatric Kidney or Liver Transplantation
- Registration Number
- NCT03100682
- Lead Sponsor
- University Hospital Heidelberg
- Brief Summary
Due to their immunosuppressive therapy, solid-organ transplant (SOT) recipients bear a 10 to 100 times higher risk of human papillomavirus (HPV)-associated malignancies than healthy individuals. The objectives of this observational, non-interventional multi-national, multi-centre research project are to gain an insight into current HPV vaccination strategies and to investigate the immune response to different routinely administered HPV vaccines in European paediatric SOT candidates and immunocompromised transplant recipients, enabling patients at risk of vaccination failure to be identified.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
- Paediatric Kidney and/or Liver transplant recipients
- Paediatric patients with CKD
- Who receive HPV vaccination according to country-specific vaccine schedule
Exclusion Criteria
- No HPV vaccination according to country-specific vaccine schedule
- No written informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immune Response to HPV vaccine Change of immune response from baseline (prior to vaccination) to 4-12 weeks after vaccination and to 18+- 3 months after vaccination will be assessed. HPV vaccine antibodies
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Children's Hospital
🇩🇪Heidelberg, Germany